Evidence map›Paper›PMID 34820261›Full record

ArticleLeukemia research reports2021

Eosinophilia characterized by a rare CCT6B mutation and responsive to tyrosine kinase inhibition: Case report and literature review.

Abhay Singh, Jeffrey Baron, Namrata Singh, Gopisree Peringeth, Eunice S Wang

Open access · goldAbstract readCase Reports
In one paragraph

Article in Leukemia research reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Abhay SinghDepartment of Medicine, Section of Hematology, Roswell Park Comprehensive Cancer Centre, Buffalo, United States of America.
Jeffrey BaronDepartment of Pharmacy, Roswell Park Comprehensive Cancer Center, Buffalo, NY, United States of America.
Namrata SinghDepartment of Medicine, Punjab Institute of Medical Sciences, Punjab, India.
Gopisree PeringethDepartment of Medicine, Section of Hematology, Roswell Park Comprehensive Cancer Centre, Buffalo, United States of America.
Eunice S WangDepartment of Medicine, Section of Hematology, Roswell Park Comprehensive Cancer Centre, Buffalo, United States of America.
Roswell Park Comprehensive Cancer Center · USPunjab Institute of Medical Sciences · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hypereosinophilic syndrome is a rare disorder arising from neoplastic, or idiopathic causes. The availability of NGS panels has increasingly identified rare mutations as underlying pathogenic events and have led to reclassification of cases of idiopathic hypereosinophilic syndrome as chronic eosinophilic leukemia(CEL). In this report, we describe a case of a young man with hypereosinophilia whose disease initially did not fit the WHO criteria for CEL but harbored a rare mutation in

Indexed as

CCT6BChronic eosinophilic leukemia-not otherwise specified (CEL-NOS)DasitinibIdiopathic hypereosinophilic syndrome (IHES)ImatinibNilotinib

Identifiers

PMID34820261
PMCPMC8602046
OpenAlexW3209853298

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.